The US government's Operation Warp Speed is accelerating every aspect of vaccine development apart from the two most important: safety and efficacy, according to Dr. Moncef Slaoui, the operation's chief adviser, who explained how the program worked to develop, manufacture and distribute a successful vaccine, and to do all that quickly.
Speaking during a prerecorded keynote interview for the Disease Prevention and Control Summit on Tuesday, Slaoui said that they are accelerating the process by “taking financial risk, running things in parallel and taking platform technologies that are predictable in their behavior, but not curtailing the understanding of safety and efficacy of the vaccine.”
Companies are modifying vaccine technologies that been tested already in people so they can move more quickly through the testing process, for instance. Plus, it is important to be able to speedily manufacture any new vaccine.
“We’re selecting very carefully and thoughtfully vaccine technologies that are very likely to work, and work for us, because we know them somewhat,” Slaoui said.
Secondly, the companies are “accelerating every single aspect of the development, except the two most critical ones, in terms of human safety and efficacy,” Slaoui said.
All of this is being done for a portfolio of vaccines, Slaoui said, “because we want at least one of them to work. And, ideally, all of them to work.”